|
PureBytes Links
Trading Reference Links
|
On Fri, 16 May 1997 13:59:19 -0400, John Galt wrote:
>Most biotech companies have "no net earnings". ;-) Look for
>partnerships and science and a strong product pipeline dealing with a
>demographically important disease if you want to play in this area.
>AGPH has all three.
>
>Regards,
>Dave Zawicki
That is a very cogent observation, Dave. Every industry has its own
way of determining winners.
On the technical side, everyone should compare the chart of CIEN
(Ciena Corp.) with AGPH (Agouron). They display the same type of
breakout. Both were in a short-term downtrend channel, and then broke
out to the upside. After sitting atop the channel resistance line
(now become support) last week, CIEN climbed from 35 to 46 this week.
Will AGPH do the same next week? I wish!
>> Take a look at Agouron Pharmaceuticals. It broke out yesterday.
>> I picked up some at open today for $74.
>>
>> Agouron recently received FDA approval for a new anti-AIDS drug,
>> Viracept. *Huge* market potential.
>
>Be careful with this one. The news on the HIV protease inhibitor was in
>the stock already. They had been in Phase II trials for most of last
>year and in December it looked like they were going to get FDA
>approval. Once the approval was granted it did make some new highs, but
>has been backing off ever since and the recent downtrend appears to be
>discounting the possibility of AGPH making another secondary offering.
>They recently made a bid for another bio-tech company which will
>strengthen their ability to formulate new compounds.
>
>I know this is mostly a technical analysis group, but it is sometimes
>worthwhile knowing the background of the company.
>
>> OTOH, no net earnings yet.
>
Hey, Dave: Who is John Galt, anyway? :-)
|